All the antibodies the immune system normally produces in response to a specific antigen are capable of marking (binding to) that antigen, but these antibodies-termed polyclonal-are varied & not identical. Monoclonal antibodies (MoAbs) that share a specific antigenic target are identical and are more sensitive to that target than are polyclonal antibodies for the same antigen. MoAbs are the products of hybridomas-cells that result from the biotech fusion of bone-marrow tumor cells and B lymphocytes. Hybridomas can be geared to produce specific MoAbs continuously. Monoclonal antibodies represent a primary sector of the biopharmaceuticals market. The specificity of mAbs against antigens has tremendous clinical value, making them effective therapeutic agents. Many large-sized pharmaceutical companies are looking at mAb research more closely after the success of products, such as Remicade and Rituxan. Processes for the purification of these antibodies will have a significant impact on a company's bottom line. Monoclonal antibodies are used in many diagnostic kits as they provide the specificity, rapidity and ease required.